especially when IMGN and our partner have so many choices to look at. But, I would assume that something from this effort will be coming to the fore in the not-to-distant future.
From the patent on the breakthrough --
It is extremely difficult to modify existing drugs without diminishing their cytotoxic potential. The disclosed invention overcomes this problem. The cell binding agent-taxane complexes permit the full measure of the cytotoxic action of the taxanes to be applied in a targeted fashion against unwanted cells only, therefore, avoiding side effects due to damage to non-targeted healthy cells.
=> This invention permits the taxanes to be target site-directed which had previously been impossible, while exhibiting a minimum of side effects. (I LIKE THIS)
Examples of medical conditions that can be treated according to the in vivo or ex vivo methods of killing selected cell populations include malignancy of any type including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, and lymphatic organs; autoimmune diseases, such as systemic lupus, rheumatoid arthritis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, AIDS, etc.; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and others.
We are fortunate that IMGN continues to attempt to innovate and diversity the platform. There are ample DMxx drugs in the various pipelines to prove the TAP concept and hopefully a couple of the current drugs can reach commercial viability. But, in the event the current drugs disappoint, it is good that another potential platform is lurking in the background.